COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Announces New Tool for Clinical Laboratories to Identify Validated Supply Alternatives for SARS-CoV-2 Testing

Clinical laboratory testing supplies, such as primers and probes, master mix, collection and media, and general reagents. Photo snaps source FDA supply tool.
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

FDA provides resource for clinical laboratories seeking to accommodate supply chain deficiencies for SARS-CoV-2 testing.

As supply chain issues continue to affect clinical laboratories performing SARS-CoV-2 testing, many laboratories have found it necessary to substitute the reagents or supplies used in tests. This substitution can be complex, as clinical laboratories must consider what supply alternatives have been validated. 

The US Food and Drug Administration (FDA) has recently released a tool that clinical laboratories can use to understand permitted substitutions. According to the FDA press release, “This 22-slide PowerPoint file contains detailed information to help support labs performing authorized COVID-19 tests. This interactive tool includes validated supply alternatives that labs can use to continue performing testing when there is a supply issue with some components of a test.”

The tool is easy to navigate and includes information about supplies that can be substituted including:

  • Swabs
  • Collection media
  • Primers and probes
  • Master mixes
  • PCR systems
  • Controls
  • Extraction systems or kits
  • General consumables 

The first page of this tool states, “This resource is intended for labs performing COVID-19 tests that are authorized. This resource includes validated supply alternatives that labs can use to continue performing testing when there is a supply issue with some components of a test.” 

As of June 12, 2020, the FDA had authorized 135 COVID-19 tests under emergency use authorization (EUA), which include 114 molecular tests, 20 antibody tests, and 1 antigen test.

Clinical laboratories may find the new FDA tool useful in accommodating supply chain deficiencies.

Related Resource:

FDA Press Release


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group